CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This stu...
Phase 1, Phase 2
Louisville, Kentucky, United States and 26 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
Louisville, Kentucky, United States and 188 other locations
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...
Phase 1
Louisville, Kentucky, United States and 29 other locations
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...
Phase 1, Phase 2
Louisville, Kentucky, United States and 31 other locations
to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non...
Phase 1
Louisville, Kentucky, United States and 9 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non...
Phase 1
Louisville, Kentucky, United States
clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two...
Phase 1, Phase 2
Louisville, Kentucky, United States and 20 other locations
bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or mo...
Phase 1
Louisville, Kentucky, United States and 28 other locations
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non...
Phase 1, Phase 2
Louisville, Kentucky, United States and 21 other locations
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targ...
Phase 1, Phase 2
Louisville, Kentucky, United States and 19 other locations
Clinical trials
Research sites
Resources
Legal